passiflora_incarnata_l
Unterschiede
Hier werden die Unterschiede zwischen zwei Versionen angezeigt.
| Beide Seiten der vorigen RevisionVorhergehende ÜberarbeitungNächste Überarbeitung | Vorhergehende Überarbeitung | ||
| passiflora_incarnata_l [2015/04/17 16:27] – andreas | passiflora_incarnata_l [2015/06/13 09:39] (aktuell) – Externe Bearbeitung 127.0.0.1 | ||
|---|---|---|---|
| Zeile 9: | Zeile 9: | ||
| [Pharmacognosy and chemotypes of passionflower (Passiflora incarnata L.). | [Pharmacognosy and chemotypes of passionflower (Passiflora incarnata L.). | ||
| Wohlmuth H, Penman KG, Pearson T, Lehmann RP. Biol Pharm Bull. 2010; | Wohlmuth H, Penman KG, Pearson T, Lehmann RP. Biol Pharm Bull. 2010; | ||
| + | |||
| + | "... the in vitro effects of a dry extract of Passiflora incarnata (sole active ingredient in Pascoflair® 425 mg) on the GABA system were investigated. The extract inhibited [3H]-GABA uptake into rat cortical synaptosomes but had no effect on GABA release and GABA transaminase activity. Passiflora incarnata inhibited concentration dependently the binding of [3H]- SR95531 to GABAA-receptors and of [3H]-CGP 54626 to GABAB-receptors. Using the [35S]-GTPγS binding assay Passiflora could be classified as an antagonist of the GABAB receptor. In contrast, the ethanol- and the benzodiazepine-site of the GABAA-receptor were not affected by this extract." | ||
| + | [Modulation of the γ‐aminobutyric acid (GABA) system by Passiflora incarnata L., Appel, K., Rose, T., Fiebich, B., Kammler, T., Hoffmann, C., Weiss, G., Phytotherapy Research, Vol.25(6), 2011, 838-843] | ||
| {{: | {{: | ||
passiflora_incarnata_l.1429288065.txt.gz · Zuletzt geändert: 2015/04/17 16:27 von andreas
